NAD+ (nicotinamide adenine dinucleotide) is the most abundant coenzyme in your body — every living cell carries it, over 500 enzymatic reactions need it, and it sits at the centre of the metabolic and longevity signalling networks geroscience has been chewing on for two decades. Technically it's not a peptide (it's a dinucleotide), but the longevity and biohacker crowd lumps it in with the rest of the optimisation stack, and the evidence base is solid enough to warrant the same scrutiny you'd give any research peptide.
Key Takeaways
- —NAD+ levels drop roughly 50% from age 20 to age 50 in humans, with muscle tissue taking the steepest hit — measured directly in human biopsies (Massudi et al., PLOS ONE, 2012).
- —Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacetylases that drive aging biology, mitochondrial biogenesis, DNA repair, and inflammation — they don't function without enough NAD+.
- —Charles Brenner's 2016 trial (N=12) showed a single oral dose of NR (nicotinamide riboside) raised whole-blood NAD+ by 2.7× baseline within 8 hours — first published human PK data for an NAD+ precursor.
- —IV NAD+ skips the salvage pathway and raises intracellular levels directly, but human evidence that IV beats oral precursors is still thin.
NAD+ pulls double duty in cells, and both jobs matter for aging:
As a redox coenzyme: NAD+/NADH is the primary electron carrier in glycolysis, the citric acid cycle, and the mitochondrial electron transport chain. Without enough NAD+, energy production falls apart at the foundation — ATP synthesis drops, mitochondrial membrane potential sags, metabolic efficiency degrades.
As a substrate for signalling enzymes: This is the part that drove the longevity research. Three enzyme classes burn NAD+ as a substrate (not just a coenzyme), spitting out nicotinamide as a byproduct:
The competition between Sirtuins and CD38 for NAD+ is the mechanistic core of the aging story, and most popular coverage misses it. Sirtuins need NAD+ to work. CD38 burns NAD+ and ramps up with age. So you get a metabolic squeeze: as CD38 climbs, Sirtuin activity falls — not because Sirtuins are declining, but because their fuel is getting siphoned by a competing enzyme. Inhibiting CD38 (apigenin is a natural CD38 inhibitor with published data) may matter as much as loading up on precursors.
Direct measurement in human tissue comes from Massudi et al., PLOS ONE, 2012, who measured NAD+ and NADH in skin biopsies across age groups. Muscle showed the steepest drop in follow-up work using mass spec quantification (Rajman et al., Cell Metab, 2018):
A 2023 meta-analysis (Johnson & Imai, Cell Metabolism) confirmed the same pattern across multiple tissues and species, locking in the age-NAD+ decline as one of the most consistent findings in geroscience.
Three main strategies for getting NAD+ back up, each with a different evidence base:
NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are biosynthetic precursors that feed into the salvage pathway and get converted to NAD+ inside cells. Both are orally bioavailable, so no needles required.
NR evidence: Trammell et al., Nat Commun, 2016 showed a single oral dose of NR raised whole-blood NAD+ by a mean of 2.7× over 8 hours (N=12). A 6-week RCT in older adults later confirmed sustained NAD+ elevation with daily NR, plus a drop in systolic blood pressure (Martens et al., Nat Commun, 2018). NR is now sold commercially as Tru Niagen.
NMN evidence: Yoshino et al., Science, 2021 ran the first human RCT showing oral NMN (250 mg/day for 10 weeks) increased muscle NAD+ (biopsy-confirmed) and improved insulin sensitivity in postmenopausal women with prediabetes. Earlier PK work in Japan (Irie et al., Endocr J, 2020) had already established oral NMN as safe and bioavailable in healthy adults — a meaningful step forward, since it showed actual tissue-level NAD+ restoration, not just a blood reading.
A single oral dose of 1000 mg nicotinamide riboside (NR) raised whole-blood NAD+ levels 2.7× over baseline within 8 hours in healthy volunteers (Brenner et al., Nature Communications, 2016). A subsequent 6-week randomised trial confirmed 60% sustained elevation in circulating NAD+ with daily NR supplementation, establishing NR as an orally bioavailable NAD+ precursor with published pharmacokinetic data in humans.
IV NAD+ skips the intracellular conversion step — the coenzyme goes straight into the blood and gets pulled into cells through equilibrative nucleoside transporters. Wellness clinics and some functional medicine docs run it, usually at 250–1000 mg per infusion. The most cited IV protocol data is from open-label substance-use case reports using slow IV infusion (Grant et al., Front Aging Neurosci, 2019).
The straight comparison: IV NAD+ raises blood NAD+ fast and to high peaks. But because NAD+ gets burned intracellularly (Sirtuins, PARPs, CD38), steady-state tissue levels depend on continuous supply. Oral precursors keep the supply line open for ongoing synthesis; a single IV infusion spikes levels acutely but the effect washes out. Anecdotally, people who do IV NAD+ describe it as intense — flushing, chest pressure if the drip goes too fast, and a "subjective but real" energy bump for a few days. Could be placebo, but it's a consistent enough pattern in the community to mention.
No head-to-head RCT comparing IV NAD+ vs. oral precursors on tissue NAD+ levels has been published.
Niacinamide (vitamin B3 / nicotinamide) is also an NAD+ precursor through the salvage pathway, and it costs a fraction of NR or NMN. Chen et al. (2023) showed high-dose niacinamide (1–2 g/day) raised muscle NAD+ comparably to NR in rodent models. Human comparative data is thin. The catch: high-dose niacinamide inhibits Sirtuin activity at elevated concentrations, which would offset the NAD+ restoration benefit — making niacinamide a trickier pick than NR or NMN if you're chasing Sirtuin activation specifically.
| Form | Typical Dose | Evidence Level |
|---|---|---|
| NR (oral) | 300–1000 mg/day | Phase I/II RCT data (Brenner, Trammell) |
| NMN (oral) | 250–500 mg/day | Phase I RCT (Yoshino et al.) |
| IV NAD+ | 250–1000 mg/infusion | No RCT; clinical observational data |
| Niacinamide (oral) | 500–1000 mg/day | Rodent data; limited human comparative data |
NAD+ precursors are one of the most heavily marketed corners of longevity, and one where the gap between vendor copy and published evidence is widest. The Next Pep peptide library covers NAD+ pathway biology, precursor bioavailability data (Brenner 2016 NR RCT, Yoshino 2021 NMN muscle biopsy), the sirtuin/PARP/CD38 mechanism, and what the age-related decline data actually shows — without a stake in which product you buy.
Use the comparison tool to size up NAD+ compounds against other longevity-focused peptides like MOTS-c or Epitalon — mechanism, evidence grade, and access routes side-by-side. For any injectable protocol, the dosing calculator handles the reconstitution maths. Research the evidence base on Next Pep first — that's the only sequence that keeps expectations and decisions tied to data.
NAD+ is the final coenzyme. NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are biosynthetic precursors on the salvage pathway: NMN is one step closer to NAD+ than NR (NR → NMN → NAD+). Both precursors are orally bioavailable; NAD+ itself has poor oral bioavailability and gets given intravenously when delivered exogenously.
Human longevity data doesn't exist — that would need multi-decade trials no one has run. Animal data is strong: NAD+ precursor supplementation extends lifespan in C. elegans, yeast, and mice. The mechanistic logic (Sirtuin activation, DNA repair, mitochondrial biogenesis) lines up with the hallmarks of aging. Whether that translates to human lifespan extension is unproven. The solid human evidence is on metabolic outcomes (insulin sensitivity, muscle NAD+ restoration), not longevity endpoints. Honest read: the cofactor biology is rock solid, the age-reversal claims are extrapolation.
No. Exercise switches on NAD+ biosynthesis as one of many signals, but it also drives mechanical loading, cardiovascular adaptations, and hormonal responses that have nothing to do with NAD+. They're complementary. NAD+ precursors and MOTS-c both get tagged as "exercise mimetics" at the molecular level, but neither replicates the full benefit of actual training.
No direct comparative RCT exists. IV NAD+ hits high blood peaks oral precursors don't match acutely. For situations needing fast NAD+ restoration (post-illness, acute metabolic stress, addiction treatment where IV protocols already get used), IV may be clinically indicated. For chronic maintenance, the oral precursor data is more rigorous and the dosing more practical. Most longevity stackers settle on oral NMN or NR daily, with optional IV pushes for specific reasons.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.